Open AccessBRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Author(s) -
Chengwen Liu,
Weiyi Peng,
Chunyu Xu,
Yanyan Lou,
Minying Zhang,
Jennifer A. Wargo,
Jie Qing Chen,
Haiyan S. Li,
Stephanie S. Watowich,
Yan Yang,
Dennie T. Frederick,
Zachary A. Cooper,
Rina M. Mbofung,
Mayra Whittington,
Keith T. Flaherty,
Scott E. Woodman,
Michael A. Davies,
Laszlo Radvanyi,
Willem W. Overwijk,
Gregory Lizée,
Patrick Hwu
Publication year - 2012
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-12-1626
Subject(s) - melanoma , cancer research , immunotherapy , in vivo , adoptive cell transfer , medicine , cell culture , immune system , antigen , t cell , immunology , biology , genetics , microbiology and biotechnology
Treatment of melanoma patients with selective BRAF inhibitors results in objective clinical responses in the majority of patients with BRAF-mutant tumors. However, resistance to these inhibitors develops within a few months. In this study, we test the hypothesis that BRAF inhibition in combination with adoptive T-cell transfer (ACT) will be more effective at inducing long-term clinical regressions of BRAF-mutant tumors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom